| Actelion Obtains Exclusive Rights for Two Potential Indications Auxilium to Receive up to $68.5 million in Aggregate Upfront, Regulatory, Pricing, Reimbursement and Sales Milestones MALVERN, Pa., and ALLSCHWIL/BASEL, Switzerland, Feb. 23, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Actelion Pharmaceuticals Ltd. (SWX: ATLN.S) announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagena...continued ALIOY AUXL consulting Drugs pharmaceutical |
Thursday, February 23, 2012
Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX( in Canada, Australia, Brazil and Mexico
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment